Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for <i>CYP2C9</i> and Nonsteroidal Anti‐Inflammatory Drugs
Katherine N. Theken, Craig R. Lee, Li Gong, Kelly E. Caudle, Christine M. Formea, Andrea Gaedigk, Teri E. Klein, José A. G. Agúndez, Tilo Großer
Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used analgesics due to their lack of addictive potential. However, NSAIDs have the potential to cause serious gastrointestinal, renal, and cardiovascular adverse events. CYP2C9 polymorphisms influence metabolism and clearance of several drugs in this class, thereby affecting drug exposure and potentially safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for NSAIDs based on CYP2C9 genotype (updates at www.cpicpgx.org).
Topics & Concepts
PharmacogeneticsMedicineCYP2C9Adverse effectNonsteroidalDrugPharmacologyGuidelinePharmacogenomicsIntensive care medicineInternal medicineGenotypeCytochrome P450BiologyBiochemistryPathologyGeneMetabolismPharmacogenetics and Drug MetabolismInflammatory mediators and NSAID effectsPharmaceutical studies and practices